This week, the first patient was dosed in a landmark trial of ER-100, the first cellular reprogramming therapy to reach people. We unpack the science behind "making cells young again": how three Yamanaka transcription factors reset the epigenetic clock without touching your DNA, why dropping the cancer-linked one matters, and the clever doxycycline "off-switch" that makes it safe enough for the clinic.

Then the practical aspects. Gene therapy is reversal in the clinic, but what about the rest population? We dig into where natural bioactives fit for everyday prevention, why ingredient synergy beats single molecules, and how AI is bringing personalized formulations to longevity.

Publications of interest:

World-first: therapy to make cells young again trialled in a person 

https://www.lifebiosciences.com/life-biosciences-announces-first-patient-dosed-in-phase-1-trial-of-er-100-for-optic-neuropathies/ 

https://clinicaltrials.gov/study/NCT07290244 

https://www.technologynetworks.com/biopharma/articles/re-setting-the-epigenetic-clock-to-reverse-cellular-aging-413392